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We noted a marked increase in healthcare-associated
(HA) methicillin-resistant Staphylococcus aureus (MRSA)
infections caused by isolates phenotypically consistent with
community-associated (CA)-MRSA strains. To study this
trend, we retrospectively examined all HA-MRSA isolates
from patients in our institution during 1999–2004. An isolate
was considered an SCCmecIV phenotype if it had antimi-
crobial drug susceptibilities consistent with typical CA-
MRSA isolates. Our phenotypic definition was validated in
a limited subset of isolates by SCCmec genotype, pulsed-
field gel electrophoresis, and multilocus sequence typing.
Among 352 patients with HA-MRSA isolates, SCCmecIV
phenotype increased from 17% in 1999 to 56% in 2003
(p<0.0001). Antimicrobial drug-susceptibility phenotype
and genotype were consistent in 21 (91%) of 23 isolates. In
a multivariate model, the SCCmec type IV phenotype was
independently associated with wound culture source, later
year of collection, and MRSA isolated earlier during hospi-
talization. In conclusion, MRSAisolates phenotypically sim-
ilar to CA strains have become the predominant isolates
associated with HA-MRSA in our hospital.
M
ethicillin-resistant  Staphylococcus aureus (MRSA)
is the most frequently identified antimicrobial
drug–resistant pathogen in US hospitals (1). The epidemi-
ology of infections caused by MRSA is rapidly changing.
In the past 10 years, infections caused by this organism
have emerged in the community. The 2 MRSA clones in
the United States most closely associated with community
outbreaks, USA400 (MW2 strain, ST1 lineage) and
USA300, often contain pvl genes and, more frequently,
have been associated with skin and soft tissue infections
(2,3). Outbreaks of community-associated (CA)–MRSA
infections have been reported in correctional facilities,
among athletic teams, among military recruits, in newborn
nurseries, and among men who have sex with men (4–7).
CA-MRSA infections now appear to be endemic in many
urban regions and cause most CA–S. aureus infections
(5,6,8–10).
CA-MRSA isolates were first recognized by distinct
resistance profiles of antimicrobial drugs that lacked
resistance to older antimicrobial drugs (11–13). Several
groups have noted these distinct susceptibility patterns
appearing in isolates from hospitalized patients. Denis et
al. noted that since 1995, MRSAisolates in Belgian hospi-
tals were losing resistance to older antimicrobial drugs
such as gentamicin and clindamycin (14). A Spanish hos-
pital experienced a decrease in gentamicin-resistant
MRSA isolates (from 97% in 1998 to 20% in 2002) and a
simultaneous increase in MRSA isolates carrying the
SCCmec type IV cassette (from 0% prevalence in 2000 to
23% prevalence in 2002) (15). A French group noted a
similar finding in their hospitals over an 11-year period
and found a correlation between isolates that contained
SCCmec type IV and susceptibility profiles to >3 antimi-
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Pharmacy, Los Angeles, Californiadistinguish between cultures obtained from patients hospi-
talized with CAinfection and those with hospital-associat-
ed (HA) infections. Thus, it is unclear whether these trends
in decreased antimicrobial drug resistance and increased
number of MRSA isolates that contained SCCmec type IV
were due to increased hospitalization of patients with CA-
MRSA infections or to an increased prevalence of isolates
containing SCCmec type IV among HA-MRSA isolates.
Some MRSA strains associated with CA infection
have been noted to cause HA infections. Outbreaks of HA
infections caused by isolates containing SCCmec type IV
have been reported from Australia and the United States.
Affected populations have included postpartum women
and patients undergoing prosthetic joint replacement
(17–19). Another recent report demonstrated that CA
strains had emerged as a substantial cause of HA blood-
stream infections (20). However, these reports are anecdot-
al, and data examining temporal trends are lacking.
At our institution, which is located in an area in which
CA-MRSA infections are endemic, we have noted a large
increase in HA infections caused by MRSA isolates that,
by assessment of antibiotic susceptibility patterns, appear
to carry the SCCmec type IV element (e.g., susceptible to
gentamicin, clindamycin, and trimethoprim-sulfamethoxa-
zole) (6,10,21). The aim of this study was to quantify this
trend over a 6-year period.
Methods
Population 
To find patients with HA-MRSA infections, we iden-
tified all cultures obtained >72 hours after hospitalization
that grew MRSA, from January 1, 1999, through
December 31, 2004, at Harbor-UCLA Medical Center, a
tertiary-care, urban, county hospital in Los Angeles
County. At this hospital, surveillance cultures for MRSA
colonization are not routinely performed; therefore, cul-
tures positive for MRSA are likely to reflect infection
rather than colonization. For a given patient, we examined
only data from the first positive culture and excluded
patients who had positive cultures both ≥72 hours and <72
hours after admission. If a patient had been hospitalized
more than once during the study period, only data from the
first hospitalization were retained. A standardized instru-
ment was used to abstract data from the medical record of
each patient. Information obtained included demographics,
admission date and time, hospital location, antimicrobial
drug susceptibility of the MRSA isolate, and time, date,
and source of the MRSA culture.
We obtained only MRSA blood isolates for molecular
typing because the clinical microbiology laboratory dis-
cards all other types of isolates after identification is com-
plete. In vitro susceptibilities were reported as minimal
inhibitory concentrations and performed with the VITEK
system (bioMérieux, Durham, NC, USA), according to the
protocols of the Clinical and Laboratory Standards
Institute (CLSI). The investigation protocol was reviewed
and approved by the Institutional Review Board of Harbor-
UCLA Medical Center.
Molecular Characterization of Strains 
Molecular typing was performed at the University of
Chicago by investigators who were blinded to the clinical
details and antibiograms of the isolates.
SCCmec Typing 
PCR was performed to detect mecA by using the
primer pair mecAF/mecAR (22). SCCmec elements were
distinguished by the molecular architecture of the ccr and
mecA complexes (21,23,24). PCR typing of SCCmec types
I–IV was performed under the conditions previously
described (24,25). SCCmec type II (ccrAB complex type 2
and mec complex class A), SCCmec type III (ccrAB com-
plex type 3 and mec complex class A), and SCCmec type
IV (ccrAB complex type 2 and mec complex class B) were
assigned according to published criteria (25). PCR primers
used to detect mecI (primers mI3/mI4), the mecR1 mem-
brane spanning region (MS) (primers mcR3/mcR4), and
the  mecR1 penicillin-binding region (PB) (primers
mcR1/mcR5) were originally reported by Suzuki et al.
(26). Screening for ccrAB complex types 1, 2, and 3
(ccrAB 1, 2 and 3) was accomplished with a multiplex
PCR assay that uses a mixture of 4 primers designed by Ito
et al., consisting of a common forward primer (β2) and
reverse primers, α2, α3, and α4 specific for ccrAB com-
plexes 1, 2, and 3. Thermocycler conditions used have
been described (27). The presence of the ccrAB gene com-
plex allotype 4 (ccr complex 4) was assessed in a separate
reaction that used the primer pair ccrA4F and ccrB4R (27).
Screening for the ccrC gene (ccr complex 5) was per-
formed with a forward primer (γF) in combination with the
reverse primer γR described by Ito et al. (28). Prototype
strains used for SCCmec typing were NCTC10442
(SCCmec I), N315 (SCCmec II), 85/2082 (SCCmec III),
MW2 (SCCmec IV), and WIS (SCCmec V). The control
strain used for detection of ccrAB4 was  S. epidermidis
strain ATCC 12228, which contains ccrAB4 in the
non–mec-containing SCCcomposite island (24).
MLST 
MLST was performed by PCR amplification and
sequencing of 7 housekeeping genes by using the primer
pairs designed by Enright et al (29). Denville Taq-Pro
Complete (Denville Scientific, Metuchen, NJ, USA) or the
Taq DNA Polymerase (Promega, Madison, WI, USA) was
used for the PCR reactions. PCR products were evaluated
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Montage (Billerica, MA, USA) plates according to manu-
facturer’s instructions. The purified templates were
sequenced at the University of Chicago Core Sequencing
Facility and evaluated with the use of Vector NTI software
(Invitrogen, Carlsbad, CA, USA). Each sequence was sub-
mitted to the MLST database website (www.mlst.net) for
assignment of the allelic profile and sequence type (ST).
Screening for pvl Genes
Isolates were screened for the lukF-PV and lukS-PV
genes encoding the components of the PVL toxin by PCR
amplification of a 433-bp product that includes a portion of
both the lukS-PV and lukF-PV ORFs by using the primer
pair luk-PV-1/ luk-PV-2 (final concentration 0.2 µM)
designed by Lina et al. (30). The thermocycler conditions
have been described (27).
Case Definition and Data Analysis 
A standardized definition of CA-MRSA infection was
created by the Centers for Disease Control and Prevention
(CDC) Active Bacterial Core Surveillance sites (31).
Using this definition, we defined HA-MRSA infections as
those MRSA infections that did not meet the definition of
CA-MRSA infections. Specifically, we defined an MRSA
isolate as HA associated if the original entry criteria of
hospitalization for >72 hours before culture acquisition
was met and if in the year before the present hospitaliza-
tion, the patient had had any 1 of the following: hospital-
ization, surgery, residency in a long-term care facility, and
hemodialysis or peritoneal dialysis, or at the present
admission had indwelling percutaneous devices or
catheters. A CA infection was defined as a culture-con-
firmed MRSA infection without any of the above criteria.
However, if the patient did not meet any of the above cri-
teria, had an infection at the time of admission, and the cul-
ture of the infection on admission was taken ≥72 hours
after admission, then the infection was considered CA. An
example of this situation would be a deep tissue infection
microbiologically diagnosed from a surgical biopsy speci-
men 4 days after the patient’s admission.
To validate our definition of HA-associated infection,
we reviewed 105 (30%) randomly selected charts of the
patients with MRSA infections identified ≥72 hours after
hospitalization. The purpose of this validation was to con-
firm that these cultures did not reflect CA infections that
were diagnosed late (>72 hours) in the hospital course. Of
note, in the CDC definition, an infection is considered HA
if it occurs >48 hours after admission. Yet, we chose >72
hours as a cut-off to more conservatively capture HA
infections, i.e., to minimize the miscategorization of CA
infections as HA infections.
We then defined MRSAstrains as having the SCCmec
type IV phenotype if the isolates were resistant to oxacillin
and susceptible to gentamicin, clindamycin, and trimetho-
prim-sulfamethoxazole. All other isolates were considered
to be phenotypically non–SCCmec type IV.
Characteristics were compared between patients
infected with the non–SCCmec type IV phenotype isolates
and those infected with SCCmec type IV phenotype iso-
lates by using a χ2 or t test, as appropriate. No adjustments
were made for multiple comparisons. Temporal trends in
the proportion of the SCCmec type IV phenotype were
compared with the Cochran-Armitage test of trends. A
multivariate analysis that predicted phenotypically
SCCmec type IV isolates was performed by using an
unconditional logistic regression model and a backward
model selection method. Ap value of <0.05 was defined as
statistically significant. Data analysis was done with SAS
software version 8.2 (SAS Institute Inc., Cary, NC, USA).
Results
Population Characteristics 
We identified 352 patients who had HA-MRSA cul-
tures; 229 (65%) were men, and the median age was 50
years (mean 49.5 years). In the subset of medical records
reviewed for validation of HA or CA status, none of the
patients’infections (0/105) fit our definition of a CAinfec-
tion. The SCCmec type IV phenotype was identified in 128
(36%) of these 352 patients. Compared with the
non–SCCmec type IV phenotype, patients with the
SCCmec type IV phenotype were younger (median age 48
vs. 54 years, p = 0.02) and had the defining culture taken
earlier in the hospitalization (median 8 vs. 15 days, p =
0.01). Finding an isolate with the SCCmec type IV pheno-
type was more likely if the culture source was from a
wound, blood, or source other than sputum (odds ratio
[OR] 2.9, 95% confidence interval [CI] 1.7–5.0, p<0.0001;
OR 2.6, 95% CI 1.2–5.7, p = 0.02; and OR 1.2, 95% CI
0.6–2.3, p = 0.69) (Table 1).
Validation of the SCCmec Phenotype Definition 
Of the 352 cultures, 35 were recovered from blood
and were potentially available for genetic analysis. We
were able to subculture 24 of the blood isolates. We could
not perform SCCmec typing on 1 of the 24 growing iso-
lates. The 23 remaining isolates were representative of
each year of the 6-year period except 1999, when no iso-
lates could be recovered.
Twelve isolates carried the SCCmec type IV element,
and 9 also carried the pvl genes (Table 2). Eleven isolates
carried the SCCmec type II element; none carried pvl. The
clinical definition of the SCCmec IV phenotype was ful-
filled by 11 (92%) of the 12 isolates that carried the
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contained SCCmec IV that was resistant to gentamicin,
clindamycin, and trimethoprim-sulfamethoxozole. The
definition of the non-SCCmec IV phenotype was fulfilled
by 10 (91%) of 11 isolates carrying the SCCmec II ele-
ment. Phenotypic case definition of SCCmec type was
highly correlated with the genotype confirmation of the
SCCmec type phenotype (p<0.0001 by Fisher exact test).
Trend and Multivariate Analysis of 
the SCCmec type IV Phenotype
The proportion of MRSA isolates with the SCCmec
type IV phenotype increased from 17% in 1999 to 56% in
2003 (p<0.0001, Figure). The proportion of isolates that
were of the SCCmec type IVphenotype in 2004 (52%) was
little changed from 2003 (Figure). In the multivariate
model, independent predictors for having an SCCmec type
IV phenotype isolate were wound source of culture (refer-
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= 0.001), culture obtained in less time after admission,
(OR 0.88 per week, 95% CI 0.8–0.98, p = 0.02), and year
of culture acquisition (p<0.0001) (Table 1).
Discussion
In many urban centers worldwide, infections due to
MRSA account for a large proportion of CA–S. aureus
infections; in some communities MRSAaccounts for more
than half of CA–S. aureus infections (6,8–10,32). There
have been reports of strains frequently associated with
community outbreaks causing HA infections, but they
have been mostly limited to case reports or case series
(17–19). To our knowledge, ours is the first investigation
quantifying the rise of MRSA isolates typical of CA dis-
ease to become the predominant strain of HA-MRSA (i.e.,
accounting for >50% of MRSAstrains) within the hospital
setting. Remarkably, at our institution the number of HA-
MRSAisolates that have a CAphenotype, which previous-
ly was uncommon, now is >50%.
Our analysis found 3 significant risk factors for an
SCCmec type IV phenotype MRSA culture. First, patients
with MRSAcultures from a wound source were more like-
ly to have the SCCmec type IV phenotype. This finding
may be understandable, given that the most common clin-
ical syndrome described with CA-MRSA infections has
been skin and soft tissue infections (10,33). In addition,
75% of CA-MRSA isolates that were genotyped carried
the pvl gene, which has a strong association with skin and
soft tissue infections (33). A second risk factor for the
SCCmec type IV phenotype was a shorter length of hospi-
tal stay before MRSAculture. This association may be due
to the increased severity of illness and coexisting condi-
tions in patients with a longer hospital stay, factors that
have been commonly associated with the traditional (non-
SCCmec type IV) HA-MRSA infections. However, meas-
ures of severity of illness and coexisting conditions were
not captured in this investigation. A third risk factor was a
later year of culture collection; the likelihood of SCCmec
type IV phenotype peaked in 2003. The rise of these iso-
lates in our hospital may be from CA-MRSA isolates
brought in from colonized persons from the community.
CA-MRSA infections in Los Angeles County have rapidly
become common and now exceed the frequency of those
caused by CA–methicillin-susceptible S. aureus (34).
Alternatively, the rise of SCCmec type IV isolates may be
a result of spread throughout our hospital by the usual
means of dissemination in a healthcare setting (e.g., hands
of healthcare workers, contaminated environment) (35) or
possibly by a combination of factors.
Exactly why the SCCmec type IV strains are success-
ful in hospital settings such as ours and others (20) is
unknown. Some evidence indicates that SCCmec type IV
strains may be more “fit” than SCCmec types II/III that
contain HA-MRSA isolates. Compared with methicillin-
susceptible  S. aureus, isolates containing SCCmec type
II/III replicate more slowly in vitro (36). Okuma et al.
found that CA-MRSA isolates that contain SCCmec type
IV replicate more rapidly than these traditional HA-MRSA
strains and argued that CA-MRSAmay have enhanced eco-
logic fitness compared with SCCmec type II/III isolates,
perhaps due simply to a shorter doubling time (37). Given
the vulnerable population within the hospital setting, it is
unclear how infections with isolates that contain SCCmec
type IV will differ in symptoms and severity from those
caused by traditional HA-MRSA isolates. On the basis of
our study and other somewhat similar reports (20), concern
is rising that USA300 strains may overtake the traditional
HA-MRSAstrains in many hospital and healthcare settings.
Our investigation had some limitations. First, the
analysis was retrospective and thus it was not possible to
prospectively identify patients with HA infections and
compare them with patients with CA infections. Although,
by means of a chart review of a subset of patients who
were selected by the criteria of a MRSA culture obtained
≥72 hrs after admission, none of these infections fulfilled
the CDC definition of a CA-MRSA infection (31).
A second limitation was that our case definition was
based on phenotypic criteria because nonbloodstream iso-
lates had been discarded and the SCCmec type could not
be validated. Traditionally, most HA-MRSAisolates in the
United States carry SCCmec type II (and to a lesser extent,
SCCmec type III) that encodes resistance to β-lactam
antimicrobial agents bleomycin, macrolide-lincosamide-
streptogamin B, aminoglycosides, and spectinomycin (38).
Gentamicin resistance occurs in most strains that carry the
SCCmec type II element but is conferred by the
aac6′–aph2′′ gene elsewhere on the chromosome and is
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Figure. Percentage of methicillin-resistant Staphylococcus aureus
(MRSA) isolates among healthcare-associated MRSAisolates that
are SCCmec type IV phenotype, 1999–2004.frequently carried by transposon Tn4001 (11,16).
Therefore, to select for isolates that did not confer a phe-
notype typical of healthcare-associated or non-SCCmec
type IV–containing isolates, the SCCmec type IV pheno-
type was defined as isolates that were resistant to oxacillin
and susceptible to gentamicin, clindamycin, and trimetho-
prim-sulfamethoxazole.
Some banked isolates did not grow, and in 1 isolate we
could not detect an SCCmec element. Of note, stored iso-
lates may lose their SCCmec elements over time (39),
which may explain our findings. Nevertheless, over the 6-
year observation period of our investigation, among iso-
lates, the phenotype and genotype definition of SCCmec
type were in agreement for >90% of isolates. Thus, we
were able to validate our case definition of an HA-MRSA
isolate with SCCmec type IV phenotype using both chart
review and SCCmec typing.
A third limitation of our investigation was that we
were able to recover only bloodstream isolates, a subset of
strains that are small and potentially nonrepresentattive.
Whether the relationship of phenotype to genotype is sim-
ilar for bloodstream and nonbloodstream infections is
unclear. A fourth limitation is that all of the patients were
from 1 institution and, therefore, may only reflect local
trends. However, as previously mentioned, reports of iso-
lates associated with the CA-MRSAinfections causing HA
infections are growing (17–20).
In summary, we found that over a 5-year span, MRSA
with a CA-MRSA phenotype has become the most com-
mon cause of HA-MRSAinfections in our institution. This
finding has important implications for MRSA epidemiolo-
gy, infection control practices, and empiric antimicrobial
drug selection.
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